EUVIMEDEUVIMED entdecken
Crossref

In silico comparative drug repurposing analysis of selected antifungal agents against SARS-CoV-2 main protease (Mpro, PDB ID: 6LU7): Molecular docking, ADMET profiling, and drug-likeness evaluation

Mohd Sameer

Innovative Medicines & Omics · 23.06.2026 · 3 (4) · 026190022

DOI: 10.36922/imo026190022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Innovative Medicines & Omics, online erschienen am 23.06.2026. Verfasst von Mohd Sameer.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS-CoV-2 main protease (Mpro, 3CLpro, PDB ID: 6LU7) cleaves viral polyproteins pp1a and pp1ab at 11 conserved recognition sites, releasing the non-structural proteins needed for replication–transcription complex assembly. Its catalytic HIS41-CYS145 dyad lacks a close human homolog, providing Mpro with a reasonable selectivity window as a drug target. Four approved antifungal azoles—posaconazole, itraconazole, fluconazole, and ketoconazole—were evaluated in this study as candidate non-covalent inhibitors against the 6LU7 crystal structure (2.16 Å) using AutoDock Vina v1.2.5 under rigid-receptor conditions. GC-376, a non-covalent Mpro inhibitor with published IC50 data, was docked under identical conditions and served as the primary scoring reference (ΔG = −6.763 kcal/mol). Nirmatrelvir was retained solely for the mechanistic context; rigid non-covalent docking cannot model its CYS145-alkylating mechanism. Posaconazole returned the strongest predicted affinity (−8.288 kcal/mol), followed by itraconazole (−8.095 kcal/mol), fluconazole (−5.068 kcal/mol), nirmatrelvir (−4.370 kcal/mol), and ketoconazole (−3.769 kcal/mol). Posaconazole occupied the HIS41-CYS145 catalytic cleft with predicted contacts at MET49 (~3.8 Å), MET165 (~4.1 Å), GLU166 (~3.3 Å), and the catalytic dyad residues HIS41 (~3.2 Å) and CYS145 (~3.5 Å). These distances were estimated from a rigid-receptor protocol and carry inherent coordinate uncertainty; they are not experimentally validated geometries. Posaconazole and itraconazole both carry multiple Lipinski violations, elevated lipophilicity (LogP > 4.5), predicted hERG II inhibition, and hepatotoxicity risk. Fluconazole showed a clean absorption, distribution, metabolism, excretion, and toxicity (ADMET) profile, with weaker predicted binding (−5.068 kcal/mol). No antiviral activity was claimed. Molecular dynamics simulation, binding free energy calculation, and in vitro Mpro inhibition assays are required before any biological inference can be drawn.

Zitieren

APA

Sameer, M. (2026). In silico comparative drug repurposing analysis of selected antifungal agents against SARS-CoV-2 main protease (Mpro, PDB ID: 6LU7): Molecular docking, ADMET profiling, and drug-likeness evaluation. Innovative Medicines & Omics, 3(4), 026190022. https://doi.org/10.36922/imo026190022

Vancouver

Sameer M. In silico comparative drug repurposing analysis of selected antifungal agents against SARS-CoV-2 main protease (Mpro, PDB ID: 6LU7): Molecular docking, ADMET profiling, and drug-likeness evaluation. Innovative Medicines & Omics. 2026;3(4):026190022. doi:10.36922/imo026190022

BibTeX
@article{Sameer2026,
  author = {Sameer, Mohd},
  title = {In silico comparative drug repurposing analysis of selected antifungal agents against SARS-CoV-2 main protease (Mpro, PDB ID: 6LU7): Molecular docking, ADMET profiling, and drug-likeness evaluation},
  journal = {Innovative Medicines & Omics},
  year = {2026},
  volume = {3},
  number = {4},
  pages = {026190022},
  doi = {10.36922/imo026190022}
}
Kostenlos starten →